CClinicalTrials.gg
Sign In
CompletedNCT03409484Updated Nov 5, 2020

Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults

An interventional study of Concord Grape Juice and Low flavoniod low essence beverage in Glycemic Response and Appetitive Behavior, sponsored by Purdue University. Completed at 1 site in United States. Open to participants aged 25 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-05.

Sponsored by Purdue University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

Assess the impact of 100% grape juice on postprandial glycemic response and subsequent appetite, food intake and cognitive function.

Read the detailed description

Investigators earlier clinical work and published literature suggest that the phenolic content and strong flavor intensity of 100% Concord grape juice hold potential beneficial effects on appetite and glycemia. Investigators aim to better understand the use of 100% grape juice modifies appetite and glycemia acutely and over the day using a 24 hour glucose monitor.

02

Conditions studied

  • Glycemic Response
  • Appetitive Behavior
03

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI between 25.0-34.9 kg/m2
  • Willingness to eat all test foods
  • Low consumer of tea and coffee, willingness to refrain from both during the 48 hours prior to test days and on the test day.
  • Fasting blood glucose below 6.1mmol/l via capillary finger-stick blood sample using a SureStep glucometer (Lifescan, Milpitas, CA)

Exclusion criteria

Exclusion Criteria:

  • Taking medications known to affect glycemia, lipid metabolism or appetite
  • Body weight fluctuation of >5kg in the past 3 months
  • Taking vitamin or other supplements
  • Smokers
  • Acute or Chronic disease
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Concord Grape Juice

    100% Concord Grape Juice

    Other: Concord Grape Juice

  • Sham comparator
    Low flavonoid low essence beverage

    Low flavonoid low essence beverage

    Other: Low flavoniod low essence beverage

  • Sham comparator
    Low flavonoid beverage

    Low flavonoid beverage

    Other: Low flavonoid beverage

Interventions

  • OtherConcord Grape Juice

    Concord Grape Juice

  • OtherLow flavoniod low essence beverage

    Low flavoniod low essence beverage

  • OtherLow flavonoid beverage

    Low flavonoid beverage

05

What researchers measure

Primary outcomes

  1. Change in blood glucose over 24 hours

    samples taken every 5 minutes for 24 hours by a continuous glucose monitor

    Time frame: 24 hours

Secondary outcomes

  1. Appetite

    Questionnaire on hunger, fullness, desire to eat, prospective consumption, thirst taken hourly on same day as grape juice intervention

    Time frame: 24 hours

06

Study locations

1 site
  • Purdue University
    West Lafayette, Indiana 47909, United States
07

References and documents

Publications

  • Coelho OGL, Alfenas RCG, Debelo H, Wightman JD, Ferruzzi MG, Mattes RD. Effects of Concord grape juice flavor intensity and phenolic compound content on glycemia, appetite and cognitive function in adults with excess body weight: a randomized double-blind crossover trial. Food Funct. 2021 Nov 15;12(22):11469-11481. doi: 10.1039/d1fo02049h. PubMed 34698750 ↗
08

Registry details

Key details

Study ID
NCT03409484
Lead sponsor
Purdue University
Collaborators
Welch's Food Corporation
Responsible party
Richard Mattes (Principle Investigator, Purdue University) — Principal investigator
First posted
Jan 24, 2018
Start date
Oct 10, 2018
Primary completion
Mar 28, 2019
Completion
Sep 20, 2019
Last update
Nov 5, 2020

Study contacts

Richard D Mattes, PhD
principal investigator · Purdue University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Purdue University

Start the discussion